STAT1d
How the ‘amyloid mafia’ took over Alzheimer’s research
Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...
Biogen drops controversial Alzheimer's drug, focuses on other treatments
Biogen will discontinue development of its controversial drug Aduhelm so it can shift efforts to other drugs, including Leqembi, which it developed with Eisai.
Wall Street Journal2y
The Science Behind Aduhelm, a Controversial New Alzheimer’s Drug
Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some ...
pharmaphorum5d
Aduhelm approval controversy dials up as FDA seeks probe
In another twist to the Aduhelm approval tale, FDA's Janet Woodcock has called for an independent investigation into the relationship between agency staffers and Biogen executives. The acting FDA ...
The TikTok Reversal And The Science Of Illogical Medical Decisions
When smart people make irrational choices, we often assume they are acting out of selfishness, stupidity or stubbornness.
pharmaphorum3d
Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go
Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.
Hosted on MSN1y
Biogen discontinues Alzheimer’s medication Aduhelm
For Aduhelm, FDA made the decision without going back to its advisory committee, and it approved the drug for all patients, even though the company’s studies were only in those early in their ...
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...
STAT29d
Federal watchdog raises some concerns about the FDA’s accelerated approval program
OIG’s report suggests Aduhelm was more of an outlier, as investigators found only three troubling instances out of a sample of 24 accelerated approval drugs. But Ivan Troy, social science ...
Boston College2y
Medicare and prescription drug costs
A Boston College Center for Retirement Research report looks at the financial implications for Medicare of Alzheimer's drug Aduhelm The recent controversy over Alzheimer’s treatment Aduhelm—criticized ...
The American Journal of Managed Care4d
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...
Seeking Alpha28d
Sarepta, Biogen drugs with accelerated approval under fire in FDA report
The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease. The FDA's ...